Last reviewed 2026-04-22 · How we verify

Levosimontane injection

Levosimontane is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, while also causing vasodilation.

Levosimontane is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, while also causing vasodilation. Used for Acute decompensated heart failure, Cardiogenic shock.

At a glance

Mechanism of action

Levosimontane works by binding to cardiac troponin C, enhancing the sensitivity of contractile proteins to calcium and thereby improving myocardial contractility. Additionally, it opens ATP-sensitive potassium channels in vascular smooth muscle, producing vasodilation of both arteries and veins. This dual mechanism makes it useful in acute decompensated heart failure by improving cardiac output while reducing cardiac workload and improving hemodynamics.

Approved indications

• Acute decompensated heart failure
• Cardiogenic shock

Common side effects

• Headache
• Hypotension
• Tachycardia
• Arrhythmias
• Nausea

Key clinical trials

• Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Levosimontane injection CI brief — competitive landscape report
• Levosimontane injection updates RSS · CI watch RSS
• Qilu Hospital of Shandong University portfolio CI